Research presented at the annual meeting of the Radiological Society of North America shows that many Black patients with Alzheimer’s disease face delays in cognitive testing and screening and are diagnosed at a later stage of the disease than White patients. In North America, around 6.7 million people aged 65…

Researchers at Washington University School of Medicine in St. Louis have discovered that a type of brain cholesterol, specifically cholesteryl esters, could be a key factor in preventing brain damage and behavioral changes associated with the overaccumulation of tau protein in the brain associated with Alzheimer’s disease. In Alzheimer’s disease,…

Researchers at the University of Wisconsin-Madison report that they have identified a protein that allows for the production of norepinephrine neurons from stem cells, a development that has significant implications for research in Alzheimer’s disease (AD), Parkinson’s disease and other psychiatric and other neurodegenerative diseases. Stem-cell-derived norepinephrine neurons are found…

More visceral abdominal fat in midlife is linked to a higher risk of Alzheimer’s disease, according to research being presented next week at the annual meeting of the Radiological Society of North America (RSNA). Visceral fat surrounds the internal organs deep in the belly. Researchers found that this “hidden” abdominal…

Renew Biotechnologies’ subsidiary Resonant recently published research in the journal Frontiers in Neurology of a new blood biomarker that promises earlier diagnosis of Alzheimer’s disease (AD). The approach, which centers on the use of cell-free DNA (cfDNA) analyzes differential methylation regions (DMRs) to identify biomarkers that can distinguish neuron-derived cfDNA…

An experimental, therapeutic vaccine developed by Araclon Biotech, a Grifols Group company, targeting a peptide implicated in Alzheimer’s disease showed good safety and immunogenicity results at Phase II. The study was not powered to test efficacy in terms of reduction in Alzheimer’s symptoms, but the company reported that individuals with…

The Alzheimer’s Drug Discovery Foundation (ADDF) and the FINGERS Brain Health Institute (FBHI) have announced a new partnership that will focus on precision preventative measures physicians can take to slow, or potentially prevent, the onset of symptoms in Alzheimer’s disease based on each patient’s molecular profile. The partnership will center…

A novel 3D human cellular model of Alzheimer’s disease (AD) mimics the interactions between brain cells and the immune system. A team led by researchers at Massachusetts General Hospital (MGH) has engineered and used the model to demonstrate that as Alzheimer’s develops, CD8+ T Cells surge into the brain and…

Researchers at Arizona State University, publishing new findings in the journal Sciences Advances, have found that an Alzheimer’s disease (AD) genetic risk marker may have fertility benefits in women. The Apolipoprotein-ε4 (APOE-ε4) allele has been well studied and implicated in numerous studies for increased risk for a variety of diseases…

Cognitive decline is best assessed by tau PET, according to new research from a University of Geneva (UNIGE) and Geneva University Hospitals (HUG) team. Their results, the researchers say, support incorporating tau PET into the routine clinical evaluation and provide patients with early and individualized care. This work is published…

An investigational vaccine for Alzheimer’s disease has shown promise in improving awareness and behavior, according to preliminary research in mice presented this week at an American Heart Association meeting. The vaccine targets overexpression of senescence-associated glycoprotein (SAGP), which has been implicated in Alzheimer’s disease. In a mouse model of the…

A study led by Case Western Reserve University in Cleveland shows loss of a protein called nuclear factor erythroid 2-related factor 2 (NRF2) in the brain contributes to oxidative stress related corrosion and neurodegeneration in Alzheimer’s disease. As reported in the journal PNAS, the researchers discovered that another protein, actin-associated…

Researchers at the Max Delbrück Center for Molecular Medicine in Berlin, have discovered elevated levels of a protein known as Arl8b in Alzheimer’s disease brain models, marking it as a potential target for treatment of the condition. The most widely known biomarkers for Alzheimer’s disease are amyloid beta plaques and…

In preliminary in vitro laboratory tests, researchers at the University of Verona in Italy have identified chemical compounds present in espresso coffee that are able to inhibit tau protein aggregation—an important process in Alzheimer’s disease pathology. Nearly 75 percent of Americans drink coffee every day, making it one of the…

Eli Lilly’s new Alzheimer’s drug, donanemab, significantly slows cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD), according to full results from the Phase III TRAILBLAZER-ALZ 2 study. The results support Lilly’s application for regulatory approval to treat people with amyloid-positive early symptomatic Alzheimer’s disease (either mild…